- $106.64m
- $100.07m
Brief: Polypid reports Q2 results
PolyPid Ltd expected to post a loss of 62 cents a share - Earnings Preview
Brief: PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma
Brief: PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role Of CEO
Brief: PolyPid Announces Completion Of Enrollment In Phase 3 Shield I Trial Of D-Plex₁₀₀
PolyPid climbs after data safety panel recommendation on late-stage trial
Brief: Polypid Announces Recommendation By Data Safety Monitoring Board To Conclude Enrollment Of Phase 3 Shield I Trial Of D-Plex100
PolyPid Ltd reports results for the quarter ended in March - Earnings Summary
Brief: Polypid Provides Corporate Update And Reports First Quarter 2022 Financial Results
PolyPid Ltd expected to post a loss of 64 cents a share - Earnings Preview
Brief: PolyPid Secures $15 Million Non-Dilutive Secured Term Loan Facility
PolyPid Ltd reports results for the quarter ended in December - Earnings Summary
Brief: PolyPid Reports Fourth Quarter And Full-Year 2021 Financial Results
PolyPid Ltd expected to post a loss of 56 cents a share - Earnings Preview
Brief: Polypid Announces Planned CEO Transition
Brief: Polypid Announces 500Th Patient Enrolled In Shield I Phase 3 Clinical Trial Of D-Plex₁₀₀ In Abdominal Surgery
PolyPid Ltd reports results for the quarter ended in September - Earnings Summary
Brief: Polypid Ltd. Reports Third Quarter 2021 Financial Results And Provides Corporate Update
PolyPid Ltd expected to post a loss of 62 cents a share - Earnings Preview